A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer-Reference-Cited by-同舟云学术

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Published:2017-09 Issue:3 Volume:146 Page:484-490
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Kristeleit Rebecca,Davidenko Irina,Shirinkin Vadim^ORCID,El-Khouly Fatima,Bondarenko Igor,Goodheart Michael J.,Gorbunova Vera^ORCID,Penning Carol A.,Shi Jack G.,Liu Xiangdong,Newton Robert C.,Zhao Yufan,Maleski Janet,Leopold Lance,Schilder Russell J.

Funder

Incyte Corporation

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference35 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J. Clin.,2016

2. Clinical epidemiology of epithelial ovarian cancer in the UK;Doufekas;Int. J. Womens Health,2014

3. Recent progress in the diagnosis and treatment of ovarian cancer;Jelovac;CA Cancer J. Clin.,2011

4. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential;Luvero;Ther. Adv. Med. Oncol.,2014

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

2. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression;International Immunopharmacology;2024-08

3. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression;Cancer Research Communications;2024-03-18

4. Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME);Heliyon;2024-03

5. Treatment Approaches for Platinum-Resistant Ovarian Cancer;Journal of Clinical Oncology;2024-01-10